USP Volunteer Profile: Developing the COVID-19 Vaccine Handling Toolkit...
USP’s success in its mission to improve global public health through creation of standards and related programs depends in large part on the work of volunteers.
Since the start of the pandemic, the U.S. government has allocated over $34 billon to improve U.S. medicines supply chain resilience.
Access to quality raw materials and increased stakeholder collaboration are needed to help ensure availability of monoclonal antibody (mAb) treatments for COVID-19 in low- and middle-income countries (LMICs).
In simple terms, risk is the possibility of something bad happening. It’s the uncertainty around the consequences of an activity with respect to something that we value.
COVID-19 is transforming our ways of thinking about the development, manufacture and delivery of critical medicines to patients around the world.
During the COVID-19 pandemic, we have become acutely aware of how precious time is and the potential repercussions of delays or inefficiencies.
As African nations begin to ease lockdown restrictions, health systems are bracing to prevent the novel coronavirus from spreading rapidly through their populations.